Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial

  1. Mielgo-Ayuso, Juan 1
  2. Barrenechea, Lurdes 1
  3. Alcorta, Pilar 1
  4. Larrarte, Eider 2
  5. Margareto, Javier 2
  6. Labayen, Idoia 1
  1. 1 Universidad del País Vasco/Euskal Herriko Unibertsitatea
    info

    Universidad del País Vasco/Euskal Herriko Unibertsitatea

    Lejona, España

    ROR https://ror.org/000xsnr85

  2. 2 Biomedical Research Area, Tecnalia, Miñano
Revista:
British Journal of Nutrition

ISSN: 0007-1145,  1475-2662

Año de publicación: 2013

Volumen: 111

Número: 7

Páginas: 1263-1271

Tipo: Artículo

DOI: 10.1017/S0007114513003784 GOOGLE SCHOLAR

Otras publicaciones en: British Journal of Nutrition

Resumen

The aim of the present study was to examine the effects of green tea epigallocatechin-3-gallate (EGCG) on changes in body composition, energy and substrate metabolism, cardiometabolic risk factors and liver function enzymes after an energy-restricted diet intervention in obese women. In the present randomised, double-blind, placebo-controlled study, eighty-three obese (30 kg/m2>BMI < 40 kg/m2) pre-menopausal women consumed 300 mg/d of EGCG or placebo (lactose). We measured body weight and adiposity (dual-energy X-ray absorptiometry), energy expenditure and fat oxidation rates (indirect calorimetry), blood lipid levels (TAG, total cholesterol, LDL-cholesterol and HDL-cholesterol), insulin resistance, C-reactive protein and liver function markers (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, γ-glutamyltransferase, urea, bilirubin and 2-keto[1-13C]isocaproate oxidation) before and after the intervention in the EGCG and control groups. We did not find any significant difference in the changes in body weight ( − 0·3 kg, 95 % CI − 5·0, 4·3), fat mass ( − 0·7 kg, 95 % CI − 3·5, 2·1), energy (0·3 kJ/kg per d, 95 % CI − 3·1, 2·7) and fat ( − 0·1 g/min, 95 % CI − 0·03, 0·01) metabolism, homeostasis assessment model for insulin resistance (0·2, 95 % CI − 0·2, 0·7), total cholesterol ( − 0·21 mmol/l, 95 % CI − 0·55, 0·13), LDL-cholesterol ( − 0·15 mmol/l, 95 % CI − 0·50, 0·20), TAG ( − 0·14 mmol/l, 95 % CI − 0·56, 0·29) and liver function markers between the EGCG and control groups. In conclusion, the present results suggest that dietary supplementation with 300 mg/d of EGCG for 12 weeks did not enhance energy-restricted diet-induced adiposity reductions, and did not improve weight-loss-induced changes in cardiometabolic risk factors in obese Caucasian women. The intake of 300 mg/d of EGCG for 12 weeks did not cause any adverse effect on liver function biomarkers.

Referencias bibliográficas

  • 10.1371/journal.pone.0023759
  • 10.1146/annurev.pharmtox.42.082101.154309
  • 10.2165/00002018-200831060-00003
  • 10.1111/j.1365-2362.2010.02331.x
  • 10.1177/0145721706290437
  • 10.2337/diacare.27.6.1487
  • 10.1038/oby.2007.529
  • 10.1017/S0007114511005095
  • 10.1038/sj.ejcn.1602806
  • 10.1079/BJN20041061
  • 10.1007/s12011-012-9448-z
  • 10.1007/s00228-008-0610-7
  • 10.1017/S0007114509991218
  • 10.1089/acm.2009.0188
  • 10.1038/oby.2007.354
  • 10.1038/ejcn.2010.47
  • 10.3945/ajcn.2009.28157
  • 10.1016/j.clnu.2003.10.004
  • 10.1016/j.diabres.2005.08.001
  • 10.1079/BJN20051502
  • 10.1053/meta.2003.50075
  • 10.1038/sj.ejcn.1601309
  • Bose, (2008), J Nutr, 138, pp. 1677, 10.1093/jn/138.9.1677
  • 10.1016/j.jnutbio.2010.06.006
  • 10.1016/j.clnu.2008.03.007
  • Bantle, (2008), Diabetes Care, 31, pp. S61, 10.2337/dc08-S061
  • 10.1016/j.numecd.2011.03.003
  • 10.3945/jn.108.096412
  • 10.1038/ijo.2009.299
  • 10.1016/j.phrs.2010.12.013
  • 10.1080/10408399709527797
  • 10.1016/j.physbeh.2010.02.005
  • 10.1038/oby.2009.256
  • Yellapu, (2011), Can J Gastroenterol, 25, pp. 157, 10.1155/2011/174978
  • 10.1038/ijo.2009.135
  • 10.1016/j.jada.2007.05.009
  • 10.1007/s003940050057
  • 10.1017/S0007114509371779
  • 10.1017/S0007114508047727
  • 10.1038/oby.2007.176
  • 10.1079/BJN20051580
  • 10.1016/j.jada.2006.02.009
  • Dulloo, (1999), Am J Clin Nutr, 70, pp. 1040, 10.1093/ajcn/70.6.1040
  • 10.1111/j.1467-789X.2005.00170.x
  • 10.1016/j.jsgi.2005.10.006